These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8540712)

  • 21. Pharmacokinetic study of cefmenoxime (SCE 1365-CMX) in healthy adults.
    Fourtillan JB; Bryskier A; Mignot A; Borsa F; Humbert G
    Am J Med; 1984 Dec; 77(6A):28-31. PubMed ID: 6097120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Brogden RN
    Drugs; 1992 Nov; 44(5):800-34. PubMed ID: 1280568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
    Conte JE
    J Clin Pharmacol; 1994 Nov; 34(11):1066-70. PubMed ID: 7876397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty.
    Scaglione F; De Martini G; Peretto L; Ghezzi R; Baratelli M; Arcidiacono MM; Fraschini F
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2292-4. PubMed ID: 9333066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of cefotiam in humans.
    Rouan MC; Lecaillon JB; Guibert J; Modai J; Schoeller JP
    Antimicrob Agents Chemother; 1985 Feb; 27(2):177-80. PubMed ID: 3857018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.
    Schmitt-Hoffmann A; Roos B; Schleimer M; Sauer J; Man A; Nashed N; Brown T; Perez A; Weidekamm E; Kovács P
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2570-5. PubMed ID: 15215110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.
    Lüthy R; Blaser J; Bonetti A; Simmen H; Wise R; Siegenthaler W
    Antimicrob Agents Chemother; 1981 Nov; 20(5):567-75. PubMed ID: 6275776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data.
    Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of cefodizime in elderly patients with moderate or severe renal impairment.
    Veyssier P; Devillers A; Domart Y; Fourtillan JB; Bryskier A; Procyk T
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():77-81. PubMed ID: 2074255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.
    Ings RM; Reeves DS; White LO; Bax RP; Bywater MJ; Holt HA
    J Pharmacokinet Biopharm; 1985 Apr; 13(2):121-42. PubMed ID: 4057054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin.
    Jones RN; Barry AL; Thornsberry C; Wilson HW
    Antimicrob Agents Chemother; 1981 Dec; 20(6):760-8. PubMed ID: 6275785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis.
    Müller M; Rohde B; Kovar A; Georgopoulos A; Eichler HG; Derendorf H
    J Clin Pharmacol; 1997 Dec; 37(12):1108-13. PubMed ID: 9506005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose.
    Mamzoridi K; Kasteridou N; Peonides A; Niopas I
    Pharmacol Toxicol; 1996 Jun; 78(6):417-20. PubMed ID: 8829204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins].
    Kees F; Naber KG
    Infection; 1990; 18 Suppl 3():S150-4. PubMed ID: 2079377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions.
    Lakings DB; Friis JM; Brown RJ; Allen HR
    Antimicrob Agents Chemother; 1984 Dec; 26(6):802-6. PubMed ID: 6524897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of cefotaxime.
    Fu KP; Aswapokee P; Ho I; Matthijssen C; Neu HC
    Antimicrob Agents Chemother; 1979 Nov; 16(5):592-7. PubMed ID: 526000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of cefepime in patients with thermal burn injury.
    Bonapace CR; White RL; Friedrich LV; Norcross ED; Bosso JA
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2848-54. PubMed ID: 10582870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic profile of cefodizime.
    Brockmeier D; Dagrosa EE
    Infection; 1992; 20 Suppl 1():S14-7. PubMed ID: 1526669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects.
    Meyer BH; Muller FO; Luus HG; Drees B; Röthig HJ; Badian M; Eckert HG
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():63-70. PubMed ID: 1601759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.